Trial Profile

Expanded Access Program of Taletrectinib in Patients with Advanced or Metastatic ROS1-Positive NSCLC

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Taletrectinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Expanded access; Therapeutic Use
Acronyms Tale EAP
Sponsors Nuvation Bio

Most Recent Events

07 May 2025 According to Nuvation Bio media release, this expanded access program is enabling eligible patients with advanced ROS1+ NSCLC to access taletrectinib outside of the ongoing pivotal TRUST-II study.
06 Feb 2025 New trial record
03 Feb 2025 According to Nuvation Bio media, the company has initiated an Expanded Access Program (EAP) for taletrectinib in the U.S. for the treatment of patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com